Moleculin Biotech, INC Form 4 insider transactions

Donald H Picker, Chief Science Officer of Moleculin Biotech, Inc., purchased 693,332 shares of common stock on August 3, 2026.

Donald H. Picker, Chief Science Officer of Moleculin Biotech, Inc., reported transactions involving restricted stock units and common stock.

Walter V. Klemp, CEO and President of Moleculin Biotech, Inc., reported transactions involving restricted stock units and common stock.

Moleculin Biotech's Chief Financial Officer, Jonathan P. Foster, has acquired company shares through restricted stock units and exercised warrants, indicating continued investment in the company.

Moleculin Biotech's Chief Scientific Officer, Donald H. Picker, was granted 400,000 derivative securities, including stock options and performance-based restricted stock units.

Moleculin Biotech's EVP & CFO, Jonathan P. Foster, was granted 600,000 stock options and 400,000 performance-based restricted stock units.

Moleculin Biotech's CEO and President, Walter V. Klemp, was granted 830,000 stock options and 750,000 performance-based restricted stock units.

Moleculin Biotech Director Joy Yan acquired 150,000 stock options with an exercise price of $0.49, vesting in November 2026.

Elizabeth Cermak, a Director at Moleculin Biotech, Inc. (MBRX), was granted 150,000 stock options with an exercise price of $0.49, set to vest in November 2026.

Moleculin Biotech Director Michael D. Cannon was granted 150,000 stock options with an exercise price of $0.49, vesting in November 2026.

Moleculin Biotech, Inc. Director John M. Climaco was granted 150,000 stock options with an exercise price of $0.49, vesting in November 2026.

Moleculin Biotech Director Robert E. George acquired 150,000 stock options at an exercise price of $0.49, vesting in November 2026.

Moleculin Biotech's Chief Science Officer, Donald H. Picker, reported the conversion of restricted stock units into common stock and the subsequent sale of shares to cover tax obligations.

Moleculin Biotech's CEO and President, Walter V. Klemp, reported the conversion of restricted stock units into common stock and the subsequent sale of shares to cover tax obligations.

Moleculin Biotech's Chief Financial Officer, Jonathan P. Foster, acquired common stock through RSU vesting and simultaneously sold shares to cover tax obligations.

Moleculin Biotech, Inc.'s Chief Financial Officer, Jonathan P. Foster, has reported substantial acquisitions of common stock and Series E warrants, alongside the conversion of restricted stock units and tax-related share dispositions.

Moleculin Biotech, Inc.'s CEO and President, Walter V. Klemp, has substantially increased his beneficial ownership in the company through a significant purchase in a public offering and the vesting of restricted stock units.

Donald H. Picker, Chief Science Officer of Moleculin Biotech, Inc., reported the conversion of restricted stock units into common stock and subsequent tax-related share withholdings.

Moleculin Biotech's Chief Financial Officer, Jonathan P. Foster, reported the vesting of 833 restricted stock units and the subsequent disposition of 203 shares for tax purposes on June 16, 2025.

Moleculin Biotech, Inc. CEO and President Walter V. Klemp reported the acquisition of common stock through restricted stock unit vesting and the subsequent disposition of shares for tax purposes.

Director Joy Yan acquired 10,000 stock options in Moleculin Biotech, Inc. on November 4, 2024, according to a Form 4 filing.

Director Elizabeth Cermak acquired 10,000 stock options in Moleculin Biotech, Inc. on November 4, 2024, related to her board service.

Director John M. Climaco acquired 10,000 stock options in Moleculin Biotech, Inc. on November 4, 2024, according to a Form 4 filing.

Director Robert E. George acquired stock options in Moleculin Biotech, Inc. on November 4, 2024.

Director Michael D. Cannon acquired stock options for 10,000 shares of Moleculin Biotech, Inc. at an exercise price of $2.45.

Donald H. Picker, Chief Science Officer of Moleculin Biotech, Inc., reports the acquisition of stock options and restricted stock units.

Jonathan P. Foster, CFO of Moleculin Biotech, reports acquisition of stock options and restricted stock units.

CEO Walter Klemp reports acquisition of stock options and restricted stock units in Moleculin Biotech, Inc.

Walter Klemp, CEO and President of Moleculin Biotech, reports the acquisition and disposal of common stock and restricted stock units.

Donald H. Picker, Chief Science Officer of Moleculin Biotech, Inc., reports the disposition and acquisition of common stock and restricted stock units on June 22, 2024.